CHU Limoges
- Address
- 8 avenue Dominique Larrey, 87000 Limoges, France
Bacterial Infections and Mycoses
At CHU Limoges, investigators are focusing on serious bacterial infections, especially Staphylococcus aureus bacteremia. The trials aim to lower 90‑day all‑cause mortality by testing a range of therapeutic interventions.
- Adaptive platform study evaluating new antimicrobial regimens
- Comparative analysis of standard care versus novel agents
- Real‑world assessment of treatment outcomes in bloodstream infections
Findings are expected to guide physicians in selecting the most effective strategies for life‑threatening infections across Europe.
Hemic and Lymphatic Diseases
Research at the site targets relapsed acute lymphoblastic leukemia (ALL), seeking to improve long‑term survival for patients who have already undergone treatment. Clinical efforts test immunotherapy‑based approaches to boost event‑free and disease‑free survival.
- Evaluation of antibody‑drug conjugates for remission induction
- Optimization of consolidation chemotherapy combined with targeted agents
- Study of extramedullary relapse management using novel immunotherapies
The work supports the international IntReALL BCP 2020 collaboration and strives to set new standards for pediatric and adult ALL care.
Neoplasms
The neoplasm program at CHU Limoges concentrates on hematologic cancers, with a particular emphasis on relapsed ALL, while also exploring broader oncologic implications of infection‑related complications. Trials evaluate how innovative therapies can extend disease‑free intervals and improve quality of life.
- Integration of novel immunotherapies into standard leukemia protocols
- Monitoring of long‑term outcomes after advanced consolidation strategies
- Investigation of biomarkers predictive of treatment response
By linking cancer and infection research, the center aims to deliver comprehensive care solutions that benefit patients facing complex disease trajectories.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 32 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU Limoges
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Clindamycin Hydrochloride and Drug Combination on 90-Day Mortality in Patients with Staphylococcus aureus Bacteremia | Universitair Medisch Centrum Utrecht | Phase III | Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 32 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amoxicillin | 1 | Unknown | 2023-10-26 | 2023-10-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.